The company raised its full-year revenue guidance from a range of $58 billion to $61 billion to a range of $60 billion to $62 billion. The midpoint suggests a 35% increase in sales for the full year.

Can Novo Nordisk and Eli Lilly regain their former stock market glory? A lot is riding on next year's pills ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

There’s still much more to come from the White House on tariffs, but the European Union has now reached a trade agreement ...

Eli Lilly and Company LLY is a key player in the diabetes and obesity drug market, mainly due to the significant popularity ...

Serena Williams has a new doubles partner. The 23-time Grand Slam tennis champion is working with Ro, speaking out about how ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

Serena Williams has joined telehealth company Ro as a celebrity ambassador for their weight-loss treatments. Williams will star in ads for GLP-1 medications and share her health journey post-pregnancy ...

Viking Therapeutics (VKTX 5.71%) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting ...

New pill orforglipron was associated with a significant reduction in body weight and better cholesterol, triglycerides and blood pressure.

The system, from Signos, offers three- and six-month plans ($139 and $129 a month, respectively), and the company will send all of the continuous glucose monitors a patient needs, CNBC reported. Plus: ...